Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.
about
Vaccines for preventing influenza in the elderlyReduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccinationInfluenza-related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating schoolchildrenEvaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.Advances in novel influenza vaccines: a patent review.Update on antivirals and vaccines for seasonal and potential pandemic use.The receptor binding specificity of the live attenuated influenza H2 and H6 vaccine viruses contributes to vaccine immunogenicity and protection in ferrets.Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motilityClinical data on Fluarix: an inactivated split seasonal influenza vaccine.Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines.Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Fever following immunization.Coverage and parental perceptions of influenza vaccination among parents of children aged 6 to 23 months in Hong KongIntranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses.Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine.Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus.The role of reverse genetics in the development of vaccines against respiratory viruses.Polycation-mediated delivery of siRNAs for prophylaxis and treatment of influenza virus infection.Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjectsIntranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.Intanza(®): a new intradermal vaccine for seasonal influenza.Human influenza vaccines and assessment of immunogenicity.Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.Evasion of influenza A viruses from innate and adaptive immune responses.Influenza vaccines: from whole virus preparations to recombinant protein technology.Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.Extending the cytoplasmic tail of the influenza a virus M2 protein leads to reduced virus replication in vivo but not in vitro.Prospects of HA-based universal influenza vaccine.Influenza Vaccine Effectiveness: Mysteries, Enigmas, and a Few Clues.The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.Editorial Commentary: Influenza Vaccine Effectiveness: A Glass Both Half Full and Half Empty.
P2860
Q24239997-0FB2713F-B99E-4B16-A869-6D7D8E2B4883Q24646377-DF70C8AD-D909-4869-8D6E-1EDE5F1EE1C3Q28743079-7EFEA59F-89BB-481C-826E-B1020A897DF2Q30227151-03571830-BCC6-4301-AE63-6A8A33F789F1Q30370236-A22F5F87-811B-4604-AB89-61D999BAD736Q30388514-8E78ABDF-36AA-4DB5-8210-36FB1D3ACA21Q30389265-97FAD9CE-6DB1-4C0F-9220-4974297478D9Q30410954-0E826250-7C00-4858-9200-CF92C42F448FQ30496874-D4E34BB3-C268-44B4-9F8A-4E19933F47A9Q31166045-7453C9F8-AE32-4795-8373-7EAFEA61A1EBQ33348541-46C8B03E-7F4B-4814-99C2-3129B72076CDQ33665793-571E8EA0-082C-4773-8DDD-C5AA9DA7CA5FQ34434824-110903DB-EB08-410D-B090-9DF996871AADQ34493910-0B5405BF-79A7-4AF0-A377-7D3F7638F591Q34621661-5E448531-657E-40B2-BDE7-4EFC97630458Q34700580-1176515E-2F33-4B3A-BD3B-FBA8AA3FDEDFQ35018600-39BB40A5-A07F-4BFB-92FC-8AA348EC7D89Q36099468-4A073EEA-A18B-4988-87D4-6C6EB17348F5Q36150428-1E283B5C-E589-46D7-A151-758DFF2AA0E4Q36295456-1E22516F-3C65-4FB8-8B2E-099430831680Q37601373-12A81489-91B3-4AEF-B0FC-E838164AA75BQ37706610-F1E798FD-ECB5-4CC6-A7BD-C92BA7CA35C9Q37812124-8289351C-F58B-4120-9F59-2BDABC61F41BQ37812125-C083A8CB-41E1-4FAC-A115-A63B232A75F5Q38059737-3B582FB7-5FAC-4DB0-AED3-4F008995BFC1Q38061423-1F7319E2-1244-464F-8DCF-A337572326C2Q38160083-7AE08EAB-8BDA-4DF3-B075-4449E87890D1Q39320852-80634E8A-60E7-4FC3-95E3-65F9F07B6F8EQ40055096-9B968AB7-BB22-4519-8F11-AF9957BDC81BQ41416400-49E9AE82-CDB0-4B89-BDFB-1BAEF01E9E9DQ42872289-81863DE8-8619-451C-9486-81635C051D8DQ46081672-8444F975-23B5-4BE0-8FD5-CD55AEED8062Q54513872-1A98A45E-03FB-42B7-BD93-B3E09C42D00F
P2860
Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@ast
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@en
type
label
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@ast
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@en
prefLabel
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@ast
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@en
P2093
P2860
P356
P1476
Safety, efficacy, and effectiv ...... ed population aged 5-49 years.
@en
P2093
Colin Hessel
Henry Shinefield
Iksung Cho
Julie Cordova
Kristin L Nichol
Paul M Mendelman
Robert B Belshe
Robert Walker
Steven B Black
P2860
P304
P356
10.1086/423001
P407
P577
2004-09-07T00:00:00Z